A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder

Completed · Phase 3

Conditions studied: Schizophrenia, Schizoaffective Disorder

In brief

Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The purpose of this study is to characterize the long-term safety and tolerability of lurasidone in subjects with schizophrenia or schizoaffective disorder and to allow for continued treatment for subjects completing the core study (D1050289-NCT01143077).

Key facts

Study ID

NCT01143090

Run by

Sumitomo Pharma America, Inc.

People needed

149

Starts

2010-08-01

Last updated by the study team

2015-06-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject has completed 6 weeks of treatment and all required assessments on the final study visit (Visit 8) of Study D1050289 (NCT01143077).

You may not qualify if…

• Subject is considered by the investigator to be at imminent risk of suicide or harm to self, others, or damage to property.
• Subject has a body mass index (BMI) greater than 40 or less than 18 kg/m2 (see Appendix 3 for BMI determination).

Where it is running

• K and S Professional Research Services — Little Rock, Arkansas, United States
• Synergy Clinical Research of Escondido — Escondido, California, United States
• Collaborative Neuroscience Network, Inc. — Garden Grove, California, United States
• Pacific Research Partners, LLC — Oakland, California, United States
• California Clinical Trials — Paramount, California, United States
• Pasadena Research Institute — Pasadena, California, United States
• California Neuropsychopharmacology Clinical Research Institute (CNRI), LLC — Pico Rivera, California, United States
• California Neuropsychopharmacology Clinical Research Institute (CNRI) — San Diego, California, United States
• University of California San Diego Medical Center — San Diego, California, United States
• Collaborative Neuroscience Network, South Bay — Torrance, California, United States
• Western Affiliated Research Institute — Denver, Colorado, United States
• Comprehensive NeuroScience, Inc. — Atlanta, Georgia, United States
• Medical College of Georgia — Augusta, Georgia, United States
• University of Illinois at Chicago — Chicago, Illinois, United States
• Lake Charles Clinical Trials — Lake Charles, Louisiana, United States
• St. Charles Psychiatric Associates - Midwest Research — Saint Charles, Missouri, United States
• Neurobehavioral Research, Inc. — Cedarhurst, New York, United States
• The Zucker Hillside Hospital — Glen Oaks, New York, United States
• Duke University Dept. of Psychiatry — Durham, North Carolina, United States
• Wake Forest University Baptist Medical Center — Winston-Salem, North Carolina, United States
• CRI Worldwide - Kirkbride Center — Philadelphia, Pennsylvania, United States
• FutureSearch Clinical Trials, LP — Austin, Texas, United States
• FutureSearch Trials of Dallas — Dallas, Texas, United States
• Pillar Clinical Research, LLC — Dallas, Texas, United States
• University of Texas Southwestern Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.